InsidersTradesSigma
Follow the Juno Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 20 January 2016 (Cession). Among the most active insiders: Cassidy Bernard J. The full history is free.
Analysts rate Juno Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Juno Therapeutics, Inc. 是一家生物制药公司，专注于开发用于癌症治疗的细胞疗法。它专门从事 T 细胞疗法和基因疗法。